These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29756563)

  • 41. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs.
    Dogné JM; Thiry A; Supuran CT
    Curr Pharm Des; 2008; 14(7):679-84. PubMed ID: 18336314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nano-gold displayed anti-inflammatory property via NF-kB pathways by suppressing COX-2 activity.
    Khan MA; Khan MJ
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):1149-1158. PubMed ID: 29553845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relatively selective cyclooxygenase-2 inhibitor nimesulide: What's going on?
    Caiazzo E; Ialenti A; Cicala C
    Eur J Pharmacol; 2019 Apr; 848():105-111. PubMed ID: 30689999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mediation of inflammation by cyclooxygenase-2.
    Seibert K; Masferrer J; Zhang Y; Gregory S; Olson G; Hauser S; Leahy K; Perkins W; Isakson P
    Agents Actions Suppl; 1995; 46():41-50. PubMed ID: 7610990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation.
    Masferrer JL; Kulkarni PS
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S35-40. PubMed ID: 9154274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review.
    Cruz JV; Rosa JMC; Kimani NM; Giuliatti S; Dos Santos CBR
    Curr Med Chem; 2022; 29(17):3028-3049. PubMed ID: 34514981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer.
    Clària J; Romano M
    Curr Pharm Des; 2005; 11(26):3431-47. PubMed ID: 16250846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent.
    Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S
    Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
    Famaey JP
    Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacology of cyclooxygenase 2 inhibition].
    Beubler E
    Wien Med Wochenschr; 2003; 153(5-6):95-9. PubMed ID: 12705061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective cyclooxygenase inhibitors: current status.
    Nandakishore R; Yalavarthi PR; Kiran YR; Rajapranathi M
    Curr Drug Discov Technol; 2014 Jun; 11(2):127-32. PubMed ID: 24467591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease.
    Willoughby DA; Moore AR; Colville-Nash PR
    Lancet; 2000 Feb; 355(9204):646-8. PubMed ID: 10696997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
    Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
    Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COX-2: friend or foe?
    Iezzi A; Ferri C; Mezzetti A; Cipollone F
    Curr Pharm Des; 2007; 13(16):1715-21. PubMed ID: 17584101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation.
    Wallace JL
    ScientificWorldJournal; 2006 May; 6():577-88. PubMed ID: 16752007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.
    Vuolteenaho K; Moilanen T; Moilanen E
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coumarins scaffolds as COX inhibitors.
    Revankar HM; Bukhari SN; Kumar GB; Qin HL
    Bioorg Chem; 2017 Apr; 71():146-159. PubMed ID: 28222891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism of action of antiinflammatory drugs.
    Vane JR; Botting RM
    Int J Tissue React; 1998; 20(1):3-15. PubMed ID: 9561441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.